Authors


Carol Shum

Latest:

Building Blocks for Better Balance

While block randomization has been shown to be a more frequently used form of trial randomization design, the use of dynamic randomization has been shown to have optimal treatment group balancing results.


Scott Hamilton, PhD

Latest:

An Adaptive-Block Randomization Method when Stratifying by Investigator in Small-to Medium-Sized Studies

A novel adaptive-block method of randomization to maximize the efficiency of overall treatment group balance, while maintaining balance at investigational centers in smaller sized studies, is proposed.


Kim Hung Lo

Latest:

A Comparison of Techniques for Creating Permuted Blocked Randomization Lists

Two of the most important elements to the integrity of a controlled clinical trial are the patient randomization and the treatment blinding. With a focus on block pattern distribution, four methods of randomization list creation are analyzed.




Joseph Pierro, MD

Latest:

The Benefits of Advanced Imaging Management Systems

How new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.



Daniella McCrorie

Latest:

Enhanced Site Training, Resources, and Communication

Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.


Ruth Cannata

Latest:

Enhanced Site Training, Resources, and Communication

Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.


Jennifer M. Eastabrook

Latest:

Enhanced Site Training, Resources, and Communication

Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.


Shawn Patterson Baker

Latest:

Enhanced Site Training, Resources, and Communication

Survey drills down on the preferences and experiences of clinical trial site personnel in critical function areas such as site initiation and monitoring, training, sponsor interaction, and patient recruitment and retention.


Ken Fabianovicz

Latest:

How Voice Recognition Technologies Can Be Used to Accelerate Patient Trials

Because of the growing rate of voice assistant applications, such as Alexa, healthcare and life sciences organizations are beginning to design a range of scenarios for deploying these voice assistant platforms in the clinical trial setting.


CRF Health

Latest:

The Hidden Costs of Paper-Based Clinical Outcome Assessments

Clinical trials using electronic Clinical Outcome Assessments (eCOA) benefit from compliance rates 300% higher than paper-based studies - but some sponsor shy away from eCOA adoption due to a misconception that paper diaries are cheaper. Read our eBook to understand the frequently neglected cost calculations proving that eCOA is the cost-effective and superior data collection solution for many clinical trials.


Rodeina Challand

Latest:

Operational Challenges for Biosimilar Studies

Using strategic planning to address hurdles in biosimilar development programs from the outset.


Hazel Gorham, PhD

Latest:

Operational Challenges for Biosimilar Studies

Using strategic planning to address hurdles in biosimilar development programs from the outset.


Ryan Luce

Latest:

Recruiting Diabetes Subjects

The disconnect coordinating and connecting interested patients to clinical trials is an ongoing struggle.


Terry Winchell

Latest:

The 3 Essential Factors Affecting FDA Inspection Outcome

This article focuses on the 3 essential factors that have a significant impact on the outcome of any inspection or audit. The author applies this primarily to GCP (Good Clinical Practice) inspections, but the principles are universal, being applicable to any government inspection such as the FDA (U.S. Food & Drug Administration) or industry QA (Quality Assurance) audit.


Susan M. Dallabrida PhD

Latest:

eCOA Increases Patient-Site Communication and Candor

Worldwide Clinical Trials recently announced the results of a survey that evaluated the perceptions of clinical trial site investigators who use electronic clinical outcome assessment (eCOA) technologies.


Rohit Sood, PhD, MD

Latest:

5 Common Mistakes With Spirometry in Clinical Trials

Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.


Bertrand Sohier, MD

Latest:

5 Common Mistakes With Spirometry in Clinical Trials

Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.


Eric Trueblood, MD

Latest:

5 Common Mistakes With Spirometry in Clinical Trials

Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.


Lisa Pifalo, RRT

Latest:

5 Common Mistakes With Spirometry in Clinical Trials

Solutions to overcoming the most frequent missteps when collecting valuable spirometry data in respiratory studies.


Thomas J. Newman, MD

Latest:

Personalized Medicine Development

As the popularity of personalized medicine grows the role of the CRO continues to evolve.


Steve Rosenberg

Latest:

Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey

Discover how evolving clinical trial trends are reshaping patient and site experiences—and the steps sponsors can take to stay ahead—in this conversation with uMotif CEO Steve Rosenberg at SCOPE Summit 2025.


Trevor N. Johnson

Latest:

Learning from Failure, Leveraging Biosimulation for Pediatric Drug Development Success

Pediatric trials now feature increased modeling and analytics for safer drug dosing and response.


Suzanne Minton

Latest:

Learning from Failure, Leveraging Biosimulation for Pediatric Drug Development Success

Pediatric trials now feature increased modeling and analytics for safer drug dosing and response.


Chris Smyth, PhD

Latest:

Developing New Clinical Endpoints for Immuno-Oncology Studies

Drug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.


Susan M. Dallabrida, PhD

Latest:

Improving Patient Engagement through eCOA

How the adoption of electronic clinical outcome assessment in trials can drive increased communication and patient reporting of events.



© 2025 MJH Life Sciences

All rights reserved.